PharmaMedic was delighted to support and sponsor the Excellence in Rare Diseases and Orphan Drugs category at the recent PMEA awards. Read our article to find out more.
The number of clinical trials for orphan conditions has grown significantly in the past decade. New advances in genomics and artificial intelligence also stand to improve prospects for patients with rare diseases. Read the article to learn how PharmaMedic helps translate often complex science into stakeholder value for rare disease sponsors and deliver new medicines to patients who need them.
